{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:02:36Z","timestamp":1793152956450,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/nrrheum.2016.100","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T05:00:41Z","timestamp":1468472441000},"page":"456-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["Treatment of primary Sj\u00f6gren syndrome"],"prefix":"10.1038","volume":"12","author":[{"given":"Alain","family":"Saraux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Pers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"BFnrrheum2016100_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox, R. I. Sj\u00f6gren's syndrome. Lancet 366, 321\u2013331 (2005).","journal-title":"Lancet"},{"key":"BFnrrheum2016100_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12016-014-8431-1","volume":"49","author":"D Cornec","year":"2015","unstructured":"Cornec, D. et al. The differential diagnosis of dry eyes, dry mouth, and parotidomegaly: a comprehensive review. Clin. Rev. Allergy Immunol. 49, 278\u2013287 (2015).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"BFnrrheum2016100_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard.2006.052647","volume":"66","author":"J Pijpe","year":"2007","unstructured":"Pijpe, J. et al. Progression of salivary gland dysfunction in patients with Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 66, 107\u2013112 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali, C. et al. Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61, 554\u2013558 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"SC Shiboski","year":"2012","unstructured":"Shiboski, S. C. et al. American College of Rheumatology classification criteria for Sj\u00f6gren's syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren's International Collaborative Clinical Alliance cohort. Arthritis Care Res. (Hoboken) 64, 475\u2013487 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2016100_CR6","first-page":"330","volume":"81","author":"CH Shiboski","year":"2015","unstructured":"Shiboski, C. H. & Shiboski, S. C. Proposed ACR\u2013EULAR classification criteria for Sj\u00f6gren's syndrome: development and validation [abstract S1.1]. Scand. J. Immunol. 81, 330 (2015).","journal-title":"Scand. J. Immunol."},{"key":"BFnrrheum2016100_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror, R. et al. EULAR Sj\u00f6gren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 69, 1103\u20131109 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror, R. et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sj\u00f6gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann. Rheum. Dis. 75, 382\u2013389 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror, R. et al. EULAR Sj\u00f6gren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 70, 968\u2013972 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/ard.2010.144782","volume":"70","author":"E Theander","year":"2011","unstructured":"Theander, E. et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 70, 1363\u20131368 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","volume":"91","author":"M Voulgarelis","year":"2012","unstructured":"Voulgarelis, M. et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome. Med. (Baltimore) 91, 1\u20139 (2012).","journal-title":"Med. (Baltimore)"},{"key":"BFnrrheum2016100_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","volume":"88","author":"E Baimpa","year":"2009","unstructured":"Baimpa, E., Dahabreh, I. J., Voulgarelis, M. & Moutsopoulos, H. M. Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome: clinical and pathophysiologic aspects. Med. (Baltimore) 88, 284\u2013293 (2009).","journal-title":"Med. (Baltimore)"},{"key":"BFnrrheum2016100_CR13","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1002\/art.38129","volume":"65","author":"GJ Tobon","year":"2013","unstructured":"Tobon, G. J. et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sj\u00f6gren's syndrome. Arthritis Rheum. 65, 3218\u20133227 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR14","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/art.39231","volume":"67","author":"A Papageorgiou","year":"2015","unstructured":"Papageorgiou, A. et al. A BAFF receptor His159Tyr mutation in Sj\u00f6gren's syndrome-related lymphoproliferation. Arthritis Rheumatol. 67, 2732\u20132741 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2016100_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.rbr.2015.07.004","volume":"55","author":"V Valim","year":"2015","unstructured":"Valim, V. et al. Recommendations for the treatment of Sj\u00f6gren's syndrome. Rev. Bras. Reumatol. 55, 446\u2013457 (in Portuguese) (2015).","journal-title":"Rev. Bras. Reumatol."},{"key":"BFnrrheum2016100_CR16","first-page":"CD008934","volume":"12","author":"S Furness","year":"2011","unstructured":"Furness, S., Worthington, H. V., Bryan, G., Birchenough, S. & McMillan, R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst. Rev. 12, CD008934 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrrheum2016100_CR17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ophtha.2010.12.016","volume":"118","author":"EK Akpek","year":"2011","unstructured":"Akpek, E. K. et al. Treatment of Sj\u00f6gren's syndrome-associated dry eye an evidence-based review. Ophthalmology 118, 1242\u20131252 (2011).","journal-title":"Ophthalmology"},{"key":"BFnrrheum2016100_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jama.2010.1014","volume":"304","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Siso, A. & Bosch, X. Treatment of primary Sj\u00f6gren syndrome: a systematic review. JAMA 304, 452\u2013460 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum2016100_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jtos.2014.12.001","volume":"13","author":"GN Foulks","year":"2015","unstructured":"Foulks, G. N. et al. Clinical guidelines for management of dry eye associated with Sj\u00f6gren disease. Ocul. Surf. 13, 118\u2013132 (2015).","journal-title":"Ocul. Surf."},{"key":"BFnrrheum2016100_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1034\/j.1601-0825.2002.1o816.x","volume":"8","author":"AV Amerongen","year":"2002","unstructured":"Amerongen, A. V. & Veerman, E. C. Saliva \u2014 the defender of the oral cavity. Oral Dis. 8, 12\u201322 (2002).","journal-title":"Oral Dis."},{"key":"BFnrrheum2016100_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.archoralbio.2015.03.004","volume":"60","author":"C Dawes","year":"2015","unstructured":"Dawes, C. et al. The functions of human saliva: a review sponsored by the World Workshop on Oral Medicine VI. Arch. Oral Biol. 60, 863\u2013874 (2015).","journal-title":"Arch. Oral Biol."},{"key":"BFnrrheum2016100_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12016-007-8008-3","volume":"32","author":"CP Mavragani","year":"2007","unstructured":"Mavragani, C. P. & Moutsopoulos, H. M. Conventional therapy of Sj\u00f6gren's syndrome. Clin. Rev. Allergy Immunol. 32, 284\u2013291 (2007).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"BFnrrheum2016100_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1079-2104(97)90144-X","volume":"83","author":"MP Najera","year":"1997","unstructured":"Najera, M. P. et al. Prevalence of periodontal disease in patients with Sj\u00f6gren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 83, 453\u2013457 (1997).","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"BFnrrheum2016100_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1034\/j.1600-051x.2000.027004231.x","volume":"27","author":"EA Boutsi","year":"2000","unstructured":"Boutsi, E. A., Paikos, S., Dafni, U. G., Moutsopoulos, H. M. & Skopouli, F. N. Dental and periodontal status of Sj\u00f6gren's syndrome. J. Clin. Periodontol. 27, 231\u2013235 (2000).","journal-title":"J. Clin. Periodontol."},{"key":"BFnrrheum2016100_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jcpe.12485","volume":"43","author":"B Lugonja","year":"2016","unstructured":"Lugonja, B. et al. Periodontitis prevalence and serum antibody reactivity to periodontal bacteria in primary Sj\u00f6gren's syndrome: a pilot study. J. Clin. Periodontol. 43, 26\u201333 (2016).","journal-title":"J. Clin. Periodontol."},{"key":"BFnrrheum2016100_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jbspin.2015.02.015","volume":"83","author":"M Le Gall","year":"2016","unstructured":"Le Gall, M. et al. A prospective evaluation of dental and periodontal status in patients with suspected Sj\u00f6gren's syndrome. Joint Bone Spine 83, 235\u2013236 (2016).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2016100_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/art.1780390108","volume":"39","author":"WA van der Reijden","year":"1996","unstructured":"van der Reijden, W. A., van der Kwaak, H., Vissink, A., Veerman, E. C. & Amerongen, A. V. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sj\u00f6gren's syndrome. Arthritis Rheum. 39, 57\u201363 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1834-7819.2006.tb00431.x","volume":"51","author":"PM Bartold","year":"2006","unstructured":"Bartold, P. M. Dentinal hypersensitivity: a review. Aust. Dent. J. 51, 212\u2013218 (2006).","journal-title":"Aust. Dent. J."},{"key":"BFnrrheum2016100_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.14219\/jada.2014.44","volume":"145","author":"JM Plemons","year":"2014","unstructured":"Plemons, J. M., Al-Hashimi, I. & Marek, C. L. and American Dental Association Council on Scientific Affairs. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J. Am. Dent. Assoc. 145, 867\u2013873 (2014).","journal-title":"J. Am. Dent. Assoc."},{"key":"BFnrrheum2016100_CR30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1177\/00220345880670101701","volume":"67","author":"M Steller","year":"1988","unstructured":"Steller, M., Chou, L. & Daniels, T. E. Electrical stimulation of salivary flow in patients with Sj\u00f6gren's syndrome. J. Dent. Res. 67, 1334\u20131337 (1988).","journal-title":"J. Dent. Res."},{"key":"BFnrrheum2016100_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF00300975","volume":"12","author":"N Talal","year":"1992","unstructured":"Talal, N., Quinn, J. H. & Daniels, T. E. The clinical effects of electrostimulation on salivary function of Sj\u00f6gren's syndrome patients. A placebo controlled study. Rheumatol. Int. 12, 43\u201345 (1992).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2016100_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/art.27766","volume":"63","author":"FP Strietzel","year":"2011","unstructured":"Strietzel, F. P. et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum. 63, 180\u2013190 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"FB Vivino","year":"1999","unstructured":"Vivino, F. B. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. 159, 174\u2013181 (1999).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum2016100_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/01.rhu.0000135553.08057.21","volume":"10","author":"AS Papas","year":"2004","unstructured":"Papas, A. S. et al. Successful treatment of dry mouth and dry eye symptoms in Sj\u00f6gren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J. Clin. Rheumatol. 10, 169\u2013177 (2004).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrrheum2016100_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0929-6646(09)60266-7","volume":"105","author":"CH Wu","year":"2006","unstructured":"Wu, C. H. et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sj\u00f6gren's syndrome in Taiwan \u2014 a double-blind, placebo-controlled trial. J. Formos. Med. Assoc. 105, 796\u2013803 (2006).","journal-title":"J. Formos. Med. Assoc."},{"key":"BFnrrheum2016100_CR36","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/art.510","volume":"46","author":"D Petrone","year":"2002","unstructured":"Petrone, D. et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sj\u00f6gren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 46, 748\u2013754 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR37","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","volume":"162","author":"RS Fife","year":"2002","unstructured":"Fife, R. S. et al. Cevimeline for the treatment of xerostomia in patients with Sj\u00f6gren syndrome: a randomized trial. Arch. Intern. Med. 162, 1293\u20131300 (2002).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum2016100_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10067-007-0723-x","volume":"27","author":"KC Leung","year":"2008","unstructured":"Leung, K. C. et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj\u00f6gren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin. Rheumatol. 27, 429\u2013436 (2008).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum2016100_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer, J. M. et al. Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960\u2013968 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR40","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541\u20131544 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec, V. et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann. Intern. Med. 160, 233\u2013242 (2014).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2016100_CR42","volume-title":"Management of Dry Eye","author":"SL Forstot","year":"2012","unstructured":"Forstot, S. L. & Foulks, G. N. Management of Dry Eye (Oxford Univ. Press, 2012)."},{"key":"BFnrrheum2016100_CR43","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1111\/aos.12134","volume":"91","author":"P Aragona","year":"2013","unstructured":"Aragona, P. et al. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome. Acta Ophthalmol. 91, e437\u2013e444 (2013).","journal-title":"Acta Ophthalmol."},{"key":"BFnrrheum2016100_CR44","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/bjo.83.10.1121","volume":"83","author":"PI Condon","year":"1999","unstructured":"Condon, P. I. et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w\/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br. J. Ophtalmol. 83, 1121\u20131124 (1999).","journal-title":"Br. J. Ophtalmol."},{"key":"BFnrrheum2016100_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00003226-199603000-00003","volume":"15","author":"I Toda","year":"1996","unstructured":"Toda, I., Shinozaki, N. & Tsubota, K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sj\u00f6gren's syndrome. Cornea 15, 120\u2013128 (1996).","journal-title":"Cornea"},{"key":"BFnrrheum2016100_CR46","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh, P. & Pflugfelder, S. C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj\u00f6gren syndrome. Ophthalmology 106, 811\u2013816 (1999).","journal-title":"Ophthalmology"},{"key":"BFnrrheum2016100_CR47","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","volume":"112","author":"LD Barber","year":"2005","unstructured":"Barber, L. D., Pflugfelder, S. C., Tauber, J. & Foulks, G. N. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 112, 1790\u20131794 (2005).","journal-title":"Ophthalmology"},{"key":"BFnrrheum2016100_CR48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall, K., Stevenson, O. D., Mundorf, T. K. & Reis, B. L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 107, 631\u2013639 (2000).","journal-title":"Ophthalmology"},{"key":"BFnrrheum2016100_CR49","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson, D., Tauber, J. & Reis, B. L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. Ophthalmology 107, 967\u2013974 (2000).","journal-title":"Ophthalmology"},{"key":"BFnrrheum2016100_CR50","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/ard.2002.003889","volume":"62","author":"N Tsifetaki","year":"2003","unstructured":"Tsifetaki, N. et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sj\u00f6gren's syndrome: a randomised 12 week controlled study. Ann. Rheum. Dis. 62, 1204\u20131207 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR51","doi-asserted-by":"publisher","unstructured":"Milin, M. et al. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sj\u00f6gren's syndrome. Joint Bone Spine http:\/\/dx.doi.org\/10.1016\/j.jbspin.2015.10.005 (2016).","DOI":"10.1016\/j.jbspin.2015.10.005"},{"key":"BFnrrheum2016100_CR52","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/rheumatology\/keu387","volume":"54","author":"N van Leeuwen","year":"2015","unstructured":"van Leeuwen, N. et al. Psychological profiles in patients with Sj\u00f6gren's syndrome related to fatigue: a cluster analysis. Rheumatology (Oxford) 54, 776\u2013783 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016100_CR53","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/art.24311","volume":"59","author":"B Segal","year":"2008","unstructured":"Segal, B. et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sj\u00f6gren's syndrome. Arthritis Rheum. 59, 1780\u20131787 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR54","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"JE Gottenberg","year":"2014","unstructured":"Gottenberg, J. E. et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 312, 249\u2013258 (2014).","journal-title":"JAMA"},{"key":"BFnrrheum2016100_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/ard.2007.071563","volume":"67","author":"A Hartkamp","year":"2008","unstructured":"Hartkamp, A. et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sj\u00f6gren syndrome: a randomised controlled trial. Ann. Rheum. Dis. 67, 91\u201397 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/03009740252937577","volume":"31","author":"E Theander","year":"2002","unstructured":"Theander, E., Horrobin, D. F., Jacobsson, L. T. & Manthorpe, R. Gammalinolenic acid treatment of fatigue associated with primary Sj\u00f6gren's syndrome. Scand. J. Rheumatol. 31, 72\u201379 (2002).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum2016100_CR57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/acr.20022","volume":"62","author":"LM Virkki","year":"2010","unstructured":"Virkki, L. M. et al. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sj\u00f6gren's syndrome. Arthritis Care Res. (Hoboken) 62, 118\u2013124 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2016100_CR58","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard.52.5.360","volume":"52","author":"AA Kruize","year":"1993","unstructured":"Kruize, A. A. et al. Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: a two year double blind crossover trial. Ann. Rheum. Dis. 52, 360\u2013364 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR59","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette, X. et al. Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS). Arthritis Rheum. 50, 1270\u20131276 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR60","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"V Sankar","year":"2004","unstructured":"Sankar, V. et al. Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 50, 2240\u20132245 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"X Mariette","year":"2015","unstructured":"Mariette, X. et al. Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis. 74, 526\u2013531 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR62","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","volume":"73","author":"PM Meiners","year":"2014","unstructured":"Meiners, P. M. et al. Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study). Ann. Rheum. Dis. 73, 1393\u20131396 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2474-15-21","volume":"15","author":"S Brown","year":"2014","unstructured":"Brown, S. et al. The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sj\u00f6gren's Syndrome. BMC Musculoskelet. Disord. 15, 21 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"BFnrrheum2016100_CR64","unstructured":"Bowman, S. et al. Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sj\u00f6grens syndrome [abstract 11L]. Arthritis Rheum. 67 (Suppl. 10) (2015)."},{"key":"BFnrrheum2016100_CR65","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0030-6665(05)70174-2","volume":"32","author":"DH Rice","year":"1999","unstructured":"Rice, D. H. Chronic inflammatory disorders of the salivary glands. Otolaryngol. Clin. North Am. 32, 813\u2013818 (1999).","journal-title":"Otolaryngol. Clin. North Am."},{"key":"BFnrrheum2016100_CR66","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00106-009-2076-z","volume":"58","author":"M Koch","year":"2010","unstructured":"Koch, M., Iro, H. & Zenk, J. Stenosis and other non-sialolithiasis-related obstructions of the major salivary gland ducts. Modern treatment concepts. HNO 58, 218\u2013224 (in German) (2010).","journal-title":"HNO"},{"key":"BFnrrheum2016100_CR67","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jcms.2015.06.036","volume":"43","author":"R De Luca","year":"2015","unstructured":"De Luca, R., Trodella, M., Vicidomini, A., Colella, G. & Tartaro, G. Endoscopic management of salivary gland obstructive diseases in patients with Sj\u00f6gren's syndrome. J. Craniomaxillofac. Surg. 43, 1643\u20131649 (2015).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"BFnrrheum2016100_CR68","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.joms.2015.12.019","volume":"74","author":"DJ Jager","year":"2016","unstructured":"Jager, D. J., Karagozoglu, K. H., Maarse, F., Brand, H. S. & Forouzanfar, T. Sialendoscopy of salivary glands affected by Sj\u00f6gren syndrome: a randomized controlled pilot study. J. Oral Maxillofac. Surg. 74, 1167\u20131174 (2016).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"BFnrrheum2016100_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coms.2013.09.007","volume":"26","author":"R Madero-Visbal","year":"2014","unstructured":"Madero-Visbal, R. & Milas, Z. The role of parotidectomy in Sj\u00f6gren's syndrome. Oral Maxillofac. Surg. Clin. North Am. 26, 83\u201390 (2014).","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"BFnrrheum2016100_CR70","doi-asserted-by":"crossref","unstructured":"De Vita, S. et al. Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren's syndrome: the BELISS open-label phase II study. Rheumatology (Oxford) (2015).","DOI":"10.1093\/rheumatology\/kev257"},{"key":"BFnrrheum2016100_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.berh.2015.05.002","volume":"29","author":"C Vitali","year":"2015","unstructured":"Vitali, C. & Del Papa, N. Pain in primary Sj\u00f6gren's syndrome. Best Pract. Res. Clin. Rheumatol. 29, 63\u201370 (2015).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2016100_CR72","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/rheumatology\/keq047","volume":"49","author":"AL Fauchais","year":"2010","unstructured":"Fauchais, A. L. et al. Articular manifestations in primary Sj\u00f6gren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 49, 1164\u20131172 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016100_CR73","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0002-9343(88)90365-8","volume":"85","author":"RI Fox","year":"1988","unstructured":"Fox, R. I. et al. Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine. Am. J. Med. 85, 62\u201367 (1988).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2016100_CR74","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1177\/0961203396005001081","volume":"5","author":"RI Fox","year":"1996","unstructured":"Fox, R. I., Dixon, R., Guarrasi, V. & Krubel, S. Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5, S31\u2013S36 (1996).","journal-title":"Lupus"},{"key":"BFnrrheum2016100_CR75","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00000441-200204000-00004","volume":"323","author":"S Sanders","year":"2002","unstructured":"Sanders, S. & Harisdangkul, V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci. 323, 190\u2013193 (2002).","journal-title":"Am. J. Med. Sci."},{"key":"BFnrrheum2016100_CR76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/0961203313515764","volume":"23","author":"P Brito-Zeron","year":"2014","unstructured":"Brito-Zeron, P. et al. Annular erythema in primary Sj\u00f6gren's syndrome: description of 43 non-Asian cases. Lupus 23, 166\u2013175 (2014).","journal-title":"Lupus"},{"key":"BFnrrheum2016100_CR77","first-page":"CD002954","volume":"4","author":"S Jessop","year":"2009","unstructured":"Jessop, S., Whitelaw, D. A. & Delamere, F. M. Drugs for discoid lupus erythematosus. Cochrane Database Syst. Rev. 4, CD002954 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrrheum2016100_CR78","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","volume":"65","author":"A Kuhn","year":"2011","unstructured":"Kuhn, A., Ruland, V. & Bonsmann, G. Cutaneous lupus erythematosus: update of therapeutic options part I. J. Am. Acad. Dermatol. 65, e179\u2013e193 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum2016100_CR79","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","volume":"127","author":"T Ruzicka","year":"1992","unstructured":"Ruzicka, T., Sommerburg, C., Goerz, G., Kind, P. & Mensing, H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br. J. Dermatol. 127, 513\u2013518 (1992).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2016100_CR80","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjd.13006","volume":"171","author":"A Kuhn","year":"2014","unstructured":"Kuhn, A. et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br. J. Dermatol. 171, 571\u2013579 (2014).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2016100_CR81","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals, M. et al. Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients. Med. (Baltimore) 87, 210\u2013219 (2008).","journal-title":"Med. (Baltimore)"},{"key":"BFnrrheum2016100_CR82","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","volume":"52","author":"O Palm","year":"2013","unstructured":"Palm, O. et al. Clinical pulmonary involvement in primary Sj\u00f6gren's syndrome: prevalence, quality of life and mortality \u2014 a retrospective study based on registry data. Rheumatology (Oxford) 52, 173\u2013179 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016100_CR83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s13665-012-0028-7","volume":"1","author":"M Gutsche","year":"2012","unstructured":"Gutsche, M., Rosen, G. D. & Swigris, J. J. Connective tissue disease-associated interstitial lung disease: a review. Curr. Respir. Care Rep. 1, 224\u2013232 (2012).","journal-title":"Curr. Respir. Care Rep."},{"key":"BFnrrheum2016100_CR84","doi-asserted-by":"publisher","unstructured":"Justet, A., Ottaviani, S., Dieude, P. & Taille, C. Tocilizumab for refractory organising pneumonia associated with Sj\u00f6gren's disease.BMJ Case Rep. http:\/\/dx.doi.org\/10.1136\/bcr-2014-209076 (2015).","DOI":"10.1136\/bcr-2014-209076"},{"key":"BFnrrheum2016100_CR85","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr.","year":"2014","unstructured":"King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016100_CR86","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071\u20132082 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016100_CR87","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/art.38100","volume":"65","author":"AV Goules","year":"2013","unstructured":"Goules, A. V., Tatouli, I. P., Moutsopoulos, H. M. & Tzioufas, A. G. Clinically significant renal involvement in primary Sj\u00f6gren's syndrome: clinical presentation and outcome. Arthritis Rheum. 65, 2945\u20132953 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nrneph.2015.174","volume":"12","author":"H Francois","year":"2016","unstructured":"Francois, H. & Mariette, X. Renal involvement in primary Sj\u00f6gren syndrome. Nat. Rev. Nephrol. 12, 82\u201393 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrrheum2016100_CR89","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2215\/CJN.00980209","volume":"4","author":"S Maripuri","year":"2009","unstructured":"Maripuri, S. et al. Renal involvement in primary Sj\u00f6gren's syndrome: a clinicopathologic study. Clin. J. Am. Soc. Nephrol. 4, 1423\u20131431 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrrheum2016100_CR90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12891-015-0858-x","volume":"17","author":"RD Evans","year":"2016","unstructured":"Evans, R. D., Laing, C. M., Ciurtin, C. & Walsh, S. B. Tubulointerstitial nephritis in primary Sj\u00f6gren syndrome: clinical manifestations and response to treatment. BMC Musculoskelet. Disord. 17, 2 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"BFnrrheum2016100_CR91","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215\u20131226 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR92","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","volume":"71","author":"S Arends","year":"2012","unstructured":"Arends, S. et al. Long-term follow-up of a randomised controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann. Rheum. Dis. 71, 966\u2013973 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR93","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1056\/NEJM198412133112402","volume":"311","author":"DT Felson","year":"1984","unstructured":"Felson, D. T. & Anderson, J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N. Engl. J. Med. 311, 1528\u20131533 (1984).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016100_CR94","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52, 501\u2013513 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR95","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"I Gunnarsson","year":"2007","unstructured":"Gunnarsson, I. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263\u20131272 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR96","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"JE Gottenberg","year":"2013","unstructured":"Gottenberg, J. E. et al. Efficacy of rituximab in systemic manifestations of primary Sj\u00f6gren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. 72, 1026\u20131031 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.berh.2010.01.011","volume":"25","author":"F Atzeni","year":"2011","unstructured":"Atzeni, F. et al. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract. Res. Clin. Rheumatol. 25, 165\u2013171 (2011).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2016100_CR98","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto, N. et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387, 671\u2013678 (2016).","journal-title":"Lancet"},{"key":"BFnrrheum2016100_CR99","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch, T. W., Worthington, J. W., Combs, J. J., Ilstrup, D. M. & Engel, A. G. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann. Intern. Med. 92, 365\u2013369 (1980).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2016100_CR100","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia, V. & Harisdangkul, V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44, 386\u2013389 (2005).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016100_CR101","first-page":"457","volume":"33","author":"S Colafrancesco","year":"2015","unstructured":"Colafrancesco, S. et al. Myositis in primary Sj\u00f6gren's syndrome: data from a multicentre cohort. Clin. Exp. Rheumatol. 33, 457\u2013464 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2016100_CR102","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis, C. V. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65, 314\u2013324 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR103","first-page":"1864","volume":"34","author":"CC Mok","year":"2007","unstructured":"Mok, C. C., Ho, L. Y. & To, C. H. Rituximab for refractory polymyositis: an open-label prospective study. J. Rheumatol. 34, 1864\u20131868 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2016100_CR104","doi-asserted-by":"publisher","first-page":"e000179","DOI":"10.1136\/rmdopen-2015-000179","volume":"2","author":"G Carvajal Alegria","year":"2016","unstructured":"Carvajal Alegria, G. et al. Epidemiology of neurological manifestations in Sj\u00f6gren's syndrome: data from the French ASSESS Cohort. RMD Open 2, e000179 (2016).","journal-title":"RMD Open"},{"key":"BFnrrheum2016100_CR105","first-page":"645967","volume":"2012","author":"GJ Tobon","year":"2012","unstructured":"Tobon, G. J., Pers, J. O., Devauchelle-Pensec, V. & Youinou, P. Neurological disorders in primary Sj\u00f6gren's syndrome. Autoimmune Dis. 2012, 645967 (2012).","journal-title":"Autoimmune Dis."},{"key":"BFnrrheum2016100_CR106","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","volume":"11","author":"E Nobile-Orazio","year":"2012","unstructured":"Nobile-Orazio, E. et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 11, 493\u2013502 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrrheum2016100_CR107","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","volume":"9","author":"IN van Schaik","year":"2010","unstructured":"van Schaik, I. N. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 9, 245\u2013253 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrrheum2016100_CR108","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3109\/s10165-012-0767-x","volume":"23","author":"H Yamashita","year":"2013","unstructured":"Yamashita, H. et al. Diagnosis and treatment of primary Sj\u00f6gren syndrome-associated peripheral neuropathy: a six-case series. Mod. Rheumatol. 23, 925\u2013933 (2013).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum2016100_CR109","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/acr.20495","volume":"63","author":"S Rist","year":"2011","unstructured":"Rist, S. et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sj\u00f6gren's syndrome: a national multicentric retrospective study. Arthritis Care Res. (Hoboken) 63, 1339\u20131344 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2016100_CR110","first-page":"873587","volume":"2012","author":"AR Martinez","year":"2012","unstructured":"Martinez, A. R., Nunes, M. B., Nucci, A. & Franca, M. C. Jr Sensory neuronopathy and autoimmune diseases. Autoimmune Dis. 2012, 873587 (2012).","journal-title":"Autoimmune Dis."},{"key":"BFnrrheum2016100_CR111","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000052142","volume":"45","author":"WH Chen","year":"2001","unstructured":"Chen, W. H., Yeh, J. H. & Chiu, H. C. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sj\u00f6gren's syndrome. Eur. Neurol. 45, 270\u2013274 (2001).","journal-title":"Eur. Neurol."},{"key":"BFnrrheum2016100_CR112","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian, A. et al. Efficacy of rituximab in primary Sj\u00f6gren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann. Rheum. Dis. 71, 84\u201387 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR113","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jdv.12274","volume":"28","author":"L Misery","year":"2014","unstructured":"Misery, L., Pavy-Le Traon, A., Genestet, S., Le Bec, R. & Marcorelles, P. Diagnosis of small-fibre neuropathies: comparison between quantitative sensory testing and the measurement of intraepidermal nerve fibre density. J. Eur. Acad. Dermatol. Venereol. 28, 825\u2013826 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"BFnrrheum2016100_CR114","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/brain\/awn093","volume":"131","author":"G Devigili","year":"2008","unstructured":"Devigili, G. et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131, 1912\u20131925 (2008).","journal-title":"Brain"},{"key":"BFnrrheum2016100_CR115","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.revmed.2010.08.022","volume":"32","author":"AL Fauchais","year":"2011","unstructured":"Fauchais, A. L. et al. Small fibre neuropathy in primary Sj\u00f6gren syndrome. Rev. Med. Interne 32, 142\u2013148 (in French) (2011).","journal-title":"Rev. Med. Interne"},{"key":"BFnrrheum2016100_CR116","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","volume":"72","author":"EP Flanagan","year":"2015","unstructured":"Flanagan, E. P. et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 72, 81\u201387 (2015).","journal-title":"JAMA Neurol."},{"key":"BFnrrheum2016100_CR117","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli, M. et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult. Scler. 22, 511\u2013519 (2016).","journal-title":"Mult. Scler."},{"key":"BFnrrheum2016100_CR118","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy, M. A., Wingerchuk, D. M., Palace, J., Greenberg, B. M. & Levy, M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 71, 324\u2013330 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrrheum2016100_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst, C. et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J. Neurol. 261, 1\u201316 (2014).","journal-title":"J. Neurol."},{"key":"BFnrrheum2016100_CR120","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","volume":"128","author":"P Cacoub","year":"2015","unstructured":"Cacoub, P., Comarmond, C., Domont, F., Savey, L. & Saadoun, D. Cryoglobulinemia vasculitis. Am. J. Med. 128, 950\u2013955 (2015).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2016100_CR121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2015.08.008","volume":"65","author":"B Terrier","year":"2015","unstructured":"Terrier, B. et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature. J. Autoimmun. 65, 74\u201381 (2015).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2016100_CR122","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.autrev.2015.05.013","volume":"14","author":"M Visentini","year":"2015","unstructured":"Visentini, M. et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun. Rev. 14, 889\u2013896 (2015).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum2016100_CR123","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/art.34331","volume":"64","author":"S De Vita","year":"2012","unstructured":"De Vita, S. et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64, 843\u2013853 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR124","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/rheumatology\/kew291","volume":"55","author":"AG Singh","year":"2016","unstructured":"Singh, A. G., Singh, S. & Matteson, E. L. Rate, risk factors and causes of mortality in patients with Sj\u00f6gren's syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 55, 450\u2013460 (2016).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016100_CR125","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/acr.21887","volume":"65","author":"SJ Johnsen","year":"2013","unstructured":"Johnsen, S. J. et al. Risk of non-Hodgkin's lymphoma in primary Sj\u00f6gren's syndrome: a population-based study. Arthritis Care Res. (Hoboken) 65, 816\u2013821 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2016100_CR126","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bjh.13192","volume":"168","author":"G Nocturne","year":"2015","unstructured":"Nocturne, G. & Mariette, X. Sj\u00f6gren Syndrome-associated lymphomas: an update on pathogenesis and management. Br. J. Haematol. 168, 317\u2013327 (2015).","journal-title":"Br. J. Haematol."},{"key":"BFnrrheum2016100_CR127","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.3899\/jrheum.110077","volume":"38","author":"RP Pollard","year":"2011","unstructured":"Pollard, R. P. et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sj\u00f6gren's syndrome: a retrospective clinical study. J. Rheumatol. 38, 2198\u20132208 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2016100_CR128","doi-asserted-by":"publisher","first-page":"e0116189","DOI":"10.1371\/journal.pone.0116189","volume":"10","author":"A Papageorgiou","year":"2015","unstructured":"Papageorgiou, A. et al. Predicting the outcome of Sj\u00f6gren's syndrome-associated non-hodgkin's lymphoma patients. PLoS ONE 10, e0116189 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2016100_CR129","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel, M. J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381, 1203\u20131210 (2013).","journal-title":"Lancet"},{"key":"BFnrrheum2016100_CR130","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/ard.2005.046193","volume":"65","author":"M Voulgarelis","year":"2006","unstructured":"Voulgarelis, M., Giannouli, S., Tzioufas, A. G. & Moutsopoulos, H. M. Long term remission of Sj\u00f6gren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 65, 1033\u20131037 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR131","first-page":"96","volume":"31","author":"MM Zandbelt","year":"2004","unstructured":"Zandbelt, M. M. et al. Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study. J. Rheumatol. 31, 96\u2013101 (2004).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2016100_CR132","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec, V. et al. Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57, 310\u2013317 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR133","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar4359","volume":"15","author":"F Carubbi","year":"2013","unstructured":"Carubbi, F. et al. Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res. Ther. 15, R172 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2016100_CR134","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1136\/annrheumdis-2016-209300","volume":"75","author":"D Cornec","year":"2016","unstructured":"Cornec, D. et al. Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sj\u00f6gren's syndrome? Ann. Rheum. Dis. 75, e33 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR135","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","volume":"34","author":"MI Christodoulou","year":"2010","unstructured":"Christodoulou, M. I., Kapsogeorgou, E. K. & Moutsopoulos, H. M. Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren's syndrome. J. Autoimmun. 34, 400\u2013407 (2010).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2016100_CR136","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaut.2013.02.002","volume":"41","author":"Y Thabet","year":"2013","unstructured":"Thabet, Y. et al. Epigenetic dysregulation in salivary glands from patients with primary Sj\u00f6gren's syndrome may be ascribed to infiltrating B cells. J. Autoimmun. 41, 175\u2013181 (2013).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2016100_CR137","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/art.1780400113","volume":"40","author":"L Kong","year":"1997","unstructured":"Kong, L. et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sj\u00f6gren's syndrome. Arthritis Rheum. 40, 87\u201397 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR138","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.autrev.2011.10.005","volume":"11","author":"MM Varin","year":"2012","unstructured":"Varin, M. M. et al. In Sj\u00f6gren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun. Rev. 11, 252\u2013258 (2012).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum2016100_CR139","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2249.2006.03311.x","volume":"147","author":"MP Spachidou","year":"2007","unstructured":"Spachidou, M. P. et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sj\u00f6gren's syndrome. Clin. Exp. Immunol. 147, 497\u2013503 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum2016100_CR140","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.tripleo.2010.01.006","volume":"109","author":"L Zheng","year":"2010","unstructured":"Zheng, L., Zhang, Z., Yu, C. & Yang, C. Expression of Toll-like receptors 7, 8, and 9 in primary Sj\u00f6gren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109, 844\u2013850 (2010).","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"BFnrrheum2016100_CR141","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.4049\/jimmunol.166.5.3107","volume":"166","author":"EK Kapsogeorgou","year":"2001","unstructured":"Kapsogeorgou, E. K., Moutsopoulos, H. M. & Manoussakis, M. N. Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. J. Immunol. 166, 3107\u20133113 (2001).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016100_CR142","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/art.1780290908","volume":"29","author":"RI Fox","year":"1986","unstructured":"Fox, R. I., Bumol, T., Fantozzi, R., Bone, R. & Schreiber, R. Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sj\u00f6gren's syndrome. Arthritis Rheum. 29, 1105\u20131111 (1986).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR143","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1046\/j.1365-2249.2001.01500.x","volume":"124","author":"EK Kapsogeorgou","year":"2001","unstructured":"Kapsogeorgou, E. K., Dimitriou, I. D., Abu-Helu, R. F., Moutsopoulos, H. M. & Manoussakis, M. N. Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sj\u00f6gren's syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells. Clin. Exp. Immunol. 124, 126\u2013133 (2001).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum2016100_CR144","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00918149","volume":"12","author":"DI Yannopoulos","year":"1992","unstructured":"Yannopoulos, D. I. et al. Conjunctival epithelial cells from patients with Sj\u00f6gren's syndrome inappropriately express major histocompatibility complex molecules, La(SSB) antigen, and heat-shock proteins. J. Clin. Immunol. 12, 259\u2013265 (1992).","journal-title":"J. Clin. Immunol."},{"key":"BFnrrheum2016100_CR145","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/art.38633","volume":"66","author":"SF Hamm-Alvarez","year":"2014","unstructured":"Hamm-Alvarez, S. F. et al. Tear cathepsin S as a candidate biomarker for Sj\u00f6gren's syndrome. Arthritis Rheumatol. 66, 1872\u20131881 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2016100_CR146","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/1529-0131(200102)44:2<408::AID-ANR60>3.0.CO;2-0","volume":"44","author":"G Xanthou","year":"2001","unstructured":"Xanthou, G. et al. 'Lymphoid' chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sj\u00f6gren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum. 44, 408\u2013418 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR147","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/1744666X.2014.876364","volume":"10","author":"Z Brkic","year":"2014","unstructured":"Brkic, Z. & Versnel, M. A. Type I IFN signature in primary Sj\u00f6gren's syndrome patients. Expert Rev. Clin. Immunol. 10, 457\u2013467 (2014).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"BFnrrheum2016100_CR148","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20070763","volume":"205","author":"C Guiducci","year":"2008","unstructured":"Guiducci, C. et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 205, 315\u2013322 (2008).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016100_CR149","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1186\/ar1912","volume":"8","author":"M Ittah","year":"2006","unstructured":"Ittah, M. et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sj\u00f6gren's syndrome. Arthritis Res. Ther. 8, R51 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2016100_CR150","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","volume":"190","author":"F Mackay","year":"1999","unstructured":"Mackay, F. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697\u20131710 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016100_CR151","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette, X. et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 62, 168\u2013171 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR152","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1196\/annals.1313.004","volume":"1050","author":"JO Pers","year":"2005","unstructured":"Pers, J. O. et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. NY Acad. Sci. 1050, 34\u201339 (2005).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrrheum2016100_CR153","doi-asserted-by":"publisher","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","volume":"8","author":"JE Gottenberg","year":"2013","unstructured":"Gottenberg, J. E. et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 8, e59868 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2016100_CR154","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio, L. et al. BLyS upregulation in Sj\u00f6gren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatol. (Oxford) 52, 276\u2013281 (2013).","journal-title":"Rheumatol. (Oxford)"},{"key":"BFnrrheum2016100_CR155","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1084\/jem.20021761","volume":"197","author":"DL Drayton","year":"2003","unstructured":"Drayton, D. L., Ying, X., Lee, J., Lesslauer, W. & Ruddle, N. H. Ectopic LT\u03b1\u03b2 directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J. Exp. Med. 197, 1153\u20131163 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016100_CR156","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/ni.1900","volume":"11","author":"CC Goodnow","year":"2010","unstructured":"Goodnow, C. C., Vinuesa, C. G., Randall, K. L., Mackay, F. & Brink, R. Control systems and decision making for antibody production. Nat. Immunol. 11, 681\u2013688 (2010).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum2016100_CR157","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2011.11.001","volume":"35","author":"CG Vinuesa","year":"2011","unstructured":"Vinuesa, C. G. & Cyster, J. G. How T cells earn the follicular rite of passage. Immunity 35, 671\u2013680 (2011).","journal-title":"Immunity"},{"key":"BFnrrheum2016100_CR158","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.immuni.2008.03.018","volume":"28","author":"T Ito","year":"2008","unstructured":"Ito, T. et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28, 870\u2013880 (2008).","journal-title":"Immunity"},{"key":"BFnrrheum2016100_CR159","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/art.23214","volume":"58","author":"CQ Nguyen","year":"2008","unstructured":"Nguyen, C. Q., Hu, M. H., Li, Y., Stewart, C. & Peck, A. B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sj\u00f6gren's syndrome: findings in humans and mice. Arthritis Rheum. 58, 734\u2013743 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016100_CR160","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.4049\/jimmunol.181.4.2898","volume":"181","author":"A Sakai","year":"2008","unstructured":"Sakai, A., Sugawara, Y., Kuroishi, T., Sasano, T. & Sugawara, S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sj\u00f6gren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J. Immunol. 181, 2898\u20132906 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016100_CR161","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","volume":"175","author":"GE Katsifis","year":"2009","unstructured":"Katsifis, G. E., Rekka, S., Moutsopoulos, N. M., Pillemer, S. & Wahl, S. M. Systemic and local interleukin-17 and linked cytokines associated with Sj\u00f6gren's syndrome immunopathogenesis. Am. J. Pathol. 175, 1167\u20131177 (2009).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum2016100_CR162","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1084\/jem.20131737","volume":"211","author":"H Fleige","year":"2014","unstructured":"Fleige, H. et al. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J. Exp. Med. 211, 643\u2013651 (2014).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016100_CR163","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1749-6632.2009.04651.x","volume":"1173","author":"S Lemoine","year":"2009","unstructured":"Lemoine, S., Morva, A., Youinou, P. & Jamin, C. Regulatory B cells in autoimmune diseases: how do they work? Ann. NY Acad. Sci. 1173, 260\u2013267 (2009).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrrheum2016100_CR164","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaut.2011.01.005","volume":"36","author":"S Lemoine","year":"2011","unstructured":"Lemoine, S., Morva, A., Youinou, P. & Jamin, C. Human T cells induce their own regulation through activation of B cells. J. Autoimmun. 36, 228\u2013238 (2011).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2016100_CR165","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2015.02.004","volume":"59","author":"A Nouel","year":"2015","unstructured":"Nouel, A. et al. B-cells induce regulatory T cells through TGF-\u03b2\/IDO production in A CTLA-4 dependent manner. J. Autoimmun 59, 53\u201360 (2015).","journal-title":"J. Autoimmun"},{"key":"BFnrrheum2016100_CR166","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser, E. C. & Mauri, C. Regulatory B cells: origin, phenotype, and function. Immunity 42, 607\u2013612 (2015).","journal-title":"Immunity"},{"key":"BFnrrheum2016100_CR167","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","volume":"32","author":"PA Blair","year":"2010","unstructured":"Blair, P. A. et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129\u2013140 (2010).","journal-title":"Immunity"},{"key":"BFnrrheum2016100_CR168","doi-asserted-by":"publisher","first-page":"e0133907","DOI":"10.1371\/journal.pone.0133907","volume":"10","author":"V Devauchelle-Pensec","year":"2015","unstructured":"Devauchelle-Pensec, V. et al. Which and how many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sj\u00f6gren's syndrome? PLoS ONE 10, e0133907 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2016100_CR169","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/art.39088","volume":"67","author":"S Jousse-Joulin","year":"2015","unstructured":"Jousse-Joulin, S. et al. Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sj\u00f6gren's syndrome. Arthritis Rheumatol. 67, 1623\u20131628 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2016100_CR170","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/rheumatology\/kev114","volume":"54","author":"D Cornec","year":"2015","unstructured":"Cornec, D. et al. Development of the S\u00f6gren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford) 54, 1699\u20131708 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016100_CR171","unstructured":"Oni, C. et al. Eligibility for clinical trials in primary Sj\u00f6gren's syndrome: lessons from the UK Primary Sj\u00f6gren's Syndrome Registry. Rheumatology (Oxford) (2015)."},{"key":"BFnrrheum2016100_CR172","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","volume":"138","author":"M Ono","year":"2004","unstructured":"Ono, M. et al. Therapeutic effect of cevimeline on dry eye in patients with Sj\u00f6gren's syndrome: a randomized, double-blind clinical study. Am. J. Ophthalmol. 138, 6\u201317 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum2016100_CR173","first-page":"896","volume":"25","author":"EJ Price","year":"1998","unstructured":"Price, E. J., Rigby, S. P., Clancy, U. & Venables, P. J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome. J. Rheumatol. 25, 896\u2013899 (1998).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2016100_CR174","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.45.9.732","volume":"45","author":"AA Drosos","year":"1986","unstructured":"Drosos, A. A., Skopouli, F. N., Costopoulos, J. S., Papadimitriou, C. S. & Moutsopoulos, H. M. Cyclosporin A (CyA) in primary Sj\u00f6gren's syndrome: a double blind study. Ann. Rheum. Dis. 45, 732\u2013735 (1986).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016100_CR175","doi-asserted-by":"publisher","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","volume":"7","author":"KB Norheim","year":"2012","unstructured":"Norheim, K. B., Harboe, E., Goransson, L. G. & Omdal, R. Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome \u2014 a double blind, randomised clinical trial. PLoS ONE 7, e30123 (2012).","journal-title":"PLoS ONE"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2016.100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2016.100","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2016.100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T02:38:50Z","timestamp":1718678330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2016.100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":175,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFnrrheum2016100"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2016.100","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]},"assertion":[{"value":"14 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-O.P. declares that he has received honoraria from Novartis. A.S. declares that he has received funds or honoraria from Abbvie, Bristol Myers Squibb, Chugai, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche and UCB.. V.D.-P. declares that she has received funds or honoraria from Abbvie, Bristol Myers Squibb, Chugai, MSD, Novartis, Roche and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}